Abrobo

Horizon Surgical Systems, founded in 2021 in Malibu, California, USA, was spun out of UCLA in 2021. It develops robotic systems to assist in ophthalmic surgery, particularly cataract surgery, combining AI computer vision to aid surgeon decision-making and automate repetitive surgical steps.

Series A · $30M · 2024-10

Neocis, founded in 2013 in Miami, USA, develops robotic systems to assist dental surgeries.

Undisclosed · $140M · 2024-01

Capstan Medical, founded in 2019 in Santa Cruz, California, develops robotic systems that enable physicians to implant cardiac valve replacements via catheter, eliminating the need for open-heart surgery.

Undisclosed · $110M · 2024-12

Shenzhen Ruixin Intelligent Medical Technology Co., Ltd., founded in December 2017 by three returnee PhDs — Zheng Lingxiao, Lan Hongzhi, and Ma Jun — develops an AI and surgical robotics precision diagnosis and treatment platform for cardiovascular and cerebrovascular diseases. Core products include Ruixin Score (CT-FFR non-invasive coronary functional assessment), AngioQFA coronary functional measurement system, and intracardiac ultrasound, with an AI vascular interventional surgical robot under development; the company holds 11 NMPA registration certificates and EU CE certification, with clinical partnerships at over 800 hospitals.

Strategic · 2026-07

Kangronsten (康诺思腾), founded in 2019 in Shenzhen, China, develops laparoscopic surgical robots.

Series D+ · $271M · 2025-11

Pangce Medical (磅策医疗), founded in Shanghai, China in 2019, is a developer of medical surgical robots focused on core technologies including orthopedic and surgical robots and navigation positioning. The current funding round will be used for core technology iteration, new product pipeline R&D and clinical registration, commercialization channel expansion, and global market development.

Series B · $15M · 2026-04

CMR Surgical, founded in 2014 in Cambridge, UK, sells robotic surgical systems to hospitals to assist surgeons in performing procedures for cancer and bowel disease treatment.

Undisclosed · $165M · 2023-09

Nami Surgical, founded in 2021 in Glasgow, Scotland, develops miniaturized ultrasonic medical devices for surgical applications, including high-performance compact ultrasonic scalpels designed to overcome limitations in robot-assisted surgery.

Undisclosed · $4M · 2024-05

Soundsafe Care is an Italian medical robotics startup spun off in 2023 from the BioRobotics Institute of Scuola Superiore Sant'Anna in Pisa, founded by Andrea Mariani and Laura Morchi. It develops ØSCAR, a robotic high-intensity focused ultrasound system for incision-free, radiation-free tumor ablation, first certified for veterinary use ahead of human oncology applications.

$2M

Founded in 2010 in Singapore, Biobot develops surgical robotics systems. Its flagship product Mona Lisa is an FDA-cleared, CE-marked prostate surgery robot with over 20,000 procedures completed and more than 50 units installed worldwide.

Series B · $24M · 2024-03

Scopia Surgical (also referred to as Scopia Tech) is a Montreal, Canada-based surgical navigation company founded in 2024 by CEO Gabriel Rivest and CTO Sébastien Delorme. It builds an AI surgical navigation software platform that fuses real-time spatial intelligence with patient-specific digital twins generated from CT/MRI scans — positioned as "a GPS for minimally invasive robotic surgery" — for gynaecologic, urologic and colorectal procedures, integrating into existing surgical workflows without additional tracking hardware. The roughly seven-person team is backed by Quebec innovation bodies including MAIN, Centech ETS and Medteq+.

Pre-Seed · $3M · 2026-09

iPreg Inc. (好孕行生醫), founded in 2018 in Xizhi, New Taipei City, is a reproductive-health medtech company spun out of National Yang Ming Chiao Tung University's biomedical engineering research. Its SperSort biochip platform uses antibody-free, biomimetic microfluidics to sort healthy sperm for IVF clinics, and it also offers AIVF Consultant, an AI chatbot trained on assisted reproduction for patient Q&A.